From: The long and short non-coding RNAs modulating EZH2 signaling in cancer
Cancer type | Nanocarrier | Co-delivery | In vitro/in vivo | Cell line/Animal model | Remarks | References |
---|---|---|---|---|---|---|
Bladder cancer | – | – | In vitro | T24 cells | EZH2 down-regulation by siRNA Reducing growth up to 37.9% Decreasing metastasis up to 67% | [242] |
Non-small cell lung cancer Gastric cancer | – | – | In vitro | AGS and A549 cells | Inducing cell cycle arrest at G0/G1 phase after siRNA-EZH2 application Apoptosis stimulation Caspase-3/8 activation Down-regulation of cyclin D1 and MDR1 Upregulation of p15, p21, p27 and miRNA-218 as tumor-suppressor factors | [244] |
Non-small cell lung cancer | Multifunctional nanoparticles | SiRNA-EZH2 Etoposide | In vitro In vivo | A549 cells Orthotopic lung cancer model | Reducing mRNA and protein levels of EZH2 Decreasing proliferation and invasion of cancer cells Selective targeting tumor cells via RGD modification Synergistic impact | [246] |
Glioma | Polymeric nanoparticles | – | In vitro In vivo | U87 cells Tumor-bearing mice | High transfection efficiency (up to 98%) Zeta potential of 36.7 demonstrates high stability Particle size of 35.6 nm Providing gene silencing and suppressing cancer progression | [176] |
Ovarian cancer | Iron nanoparticles | Platinum siRNA | In vitro In vivo | A2780 cells Tumor-bearing mice | Synergistic impact for overcoming drug resistance Cancer elimination Apoptosis induction | [247] |